RXi Pharmaceuticals'' CEO Dr. Geert Cauwenbergh Interviewed by The Life Sciences Report
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 06/01/15 -- Inhibition -- developing therapies that can suppress certain disease mechanisms -- is a major thrust in modern biotech. With its unique RNA interference delivery platform, spun out from the mind of a Nobel laureate, CEO Dr. Geert Cauwenbergh tells about the transformational treatments (NASDAQ: RXII) has in the pipeline, therapies that can both enrich lives and investors'' portfolios.
What is the focus of your company, RXi Pharmaceuticals Corporation?
The major focus of our company is development of therapeutics based on a proprietary platform of RNAi -- RNA interference -- as a way to reduce the level of upregulated proteins that play a role in disease. The areas that we have selected to work in at this point are dermatology and ophthalmology.
We own our self-delivering RNAi platform, and we are actively working to develop that into transformational treatments that can be used in these two areas. We also will provide licenses to other biotech companies that are interested in using our technology platform for developments in their therapeutic areas of interest.
In addition to the interference RNA technology, we have a topical immunotherapy agent that can also be used in diseases that are poorly covered, like cutaneous metastases of malignant melanoma, or for the treatment for alopecia areata (hair loss caused by an autoimmune disorder), for which there is no treatment available today...
Continue reading this interview with Dr. Geert Cauwenbergh: .
Investors rely on to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
RXi Pharmaceuticals Corporation paid The Life Sciences Report to conduct, produce and distribute the interview. Geert Cauwenbergh had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Geert Cauwenbergh and not of The Life Sciences Report or its officers.
Contact:
Brandon Fung
707-981-8107
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.06.2015 - 05:02 Uhr
Sprache: Deutsch
News-ID 1362563
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Health & Nutrition
Anmerkungen:
Diese Pressemitteilung wurde bisher 240 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RXi Pharmaceuticals'' CEO Dr. Geert Cauwenbergh Interviewed by The Life Sciences Report
"
steht unter der journalistisch-redaktionellen Verantwortung von
Streetwise Reports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
